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Available online 29 December 2010Mucin-1 (MUC1) is a heavily O-glycosylated, transmembrane protein that is expressed on the
apical surface of most secretory epithelia. In malignantly transformed epithelia, MUC1 has lost
its apical distribution, is underglycosylated and is secreted into the circulation. Due to the
underglycosylation of MUC1, cancer-speciﬁc MUC1-Tn/STn antigens, which are highly
immunogenic, become exposed. We aimed at developing a system that allows detection of
antibodies directed to the native form of MUC1 and the underglycosylated MUC1-Tn epitopes.
To this end, we made use of the Chinese Hamster Ovary (CHO) ldlD cell line stably transfected
with MUC1. This cell line has a glycosylation defect, which can be reversed by addition of
different monosaccharides to the cell culture and enables the production of cells expressing the
MUC1-Tn glycoforms. After validation with glycospeciﬁc antibodies, the CHO-ldlD MUC1
system was used to detect serum MUC1 and MUC1-Tn antibodies. Using this system, we could
conﬁrm the presence of MUC1-Tn antibodies in the serum of a patient vaccinated with a
truncated MUC1 peptide. This indicates that the CHO-ldlD MUC1 system represents a ﬂow
cytometry-based technique to detect antibodies binding to the underglycosylated MUC1
protein. This cellular system is complementary to the previously published methods to detect
MUC1 serum antibodies, since the antibodies to the native protein are evaluated and therefore
it can be effectively used for MUC1 antibody monitoring in vaccination studies as well as for
functional assays.










The transmembrane protein Mucin-1 (MUC1) is a heavily
glycosylatedprotein,which is expressed on the apical surfaceof





lsevier OA license.poietic cells (Taylor-Papadimitriou et al., 1999; Gendler, 2001).
The extracellulardomain ofMUC1 consists of a variable number
of 20 amino acid tandem repeats (HGVTSAPDTRPAPGSTAPPA).
Within each tandem repeat, two serines and three threonines
represent ﬁve potential O-glycosylation sites that are exten-
sively glycosylated (Fig. 1). The extent of glycosylation
depends on the expression of tissue-speciﬁc glycosyltrans-
ferases (Gendler, 2001).
In most adenocarcinomas and some haematological
malignancies, it has been demonstrated that MUC1 is over-
expressed, lost its apical distribution and is secreted into the
circulation (Colomer et al., 1989; Treon et al., 2000; Croce et
Fig. 1. Schematic presentation of O-glycosylation of MUC1. O-linked glycosylation is initiated by (a) polypeptide N-acetylgalactosaminyltransferases (GalNAc-Ts),
which linksN-acetylgalactosamine (GalNAc) to a serine (Ser) or threonine (Thr) of the polypeptide backbone and results in the formation of the Tn antigen. This can
be followed by sialic acid linkage to the GalNAcmoiety, which is catalyzed by (b) sialyltransferase ST6GalNAc-I, and as a consequence the sialyl-Tn (STn) antigen is
formed. If not sialylated, elongation of glycosylation can either form core 3 and 4 antigens or core 1 structures may be synthesized by (c) galactosyltransferase
ß3GalT, which add galactose (Gal) to the GalNAcmoiety, resulting in the T (core 1) antigen. Also the T antigen can become sialylated creating ST antigens by either
linking syalic acid to the GalNAc moiety, catalyzed by (d) ST6GalNAc-I, II or to the Gal moiety, catalyzed by (e) ST3Gal-I. Additionally both Gal and GalNac can
become sialylated. Linkage of more sugar moieties to the Tn antigen will result in the elongation of Core 1 structures or formation of core 2 antigens.
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Moreover, the extracellular MUC1 domain is aberrantly
glycosylated, which is caused by upregulation of sialyltrans-
ferases and downregulation of glycosyltransferases resulting
in premature termination of glycosylation (Chandrasekaran
et al., 2006; Pinho et al., 2007). Altered MUC1 expression has
been shown to increase tumorigenicity, by at least four
different mechanisms. First, altered MUC1 expression has
been coupled with enhanced metastasis formation due to
direct binding of cancer-associated MUC1 to ligands aug-
menting cancer cell–endothelial cell adhesion (Zhao et al.,
2009). Second, signalling of the intracellular MUC1 domain is
responsible for stabilisation of growth factor receptors
thereby enhancing cell proliferation (Pochampalli et al.,
2007). Third, MUC1 directly binds p53 inducing decreased
production of apoptotic genes thereby supporting cell
survival (Wei et al., 2005). Fourth, overexpression of MUC1
can reduce intercellular adhesion due to steric hindrance,
allowing tumour cells to escape from immune recognition
(van de Wiel-van Kemenade et al., 1993).
Next to the tumour supporting capacity of MUC1,
alteration of MUC1 can also increase the immunogenicity of
tumour cells. Due to decreased MUC1 glycosylation, new
tumour-associated epitopes, whichwere normallymasked by
large sugar moieties, become exposed (Taylor-Papadimitriouet al., 2002). MUC1-associated antigens frequently expressed
in cancer are the immunogenic Tn (GalNAc-) and T (Galβ1-
3GalNAc-) antigens along with their sialylated versions (ST
and STn) (Brockhausen, 2006; Tarp et al., 2007). Since it has
been suggested that these antigens are not subjected to
immune-tolerance, they represent attractive tumour-associ-
ated antigens to target with immunotherapy (Sorensen et al.,
2006; Cloosen et al., 2007).
The immunogenicity of MUC1 has been conﬁrmed by the
detection of anti-MUC1 antibodies in the serum of healthy
controls, as well as cancer patients (Richards et al., 1998). In
many malignancies it has been demonstrated that MUC1
serum antibodies, which are able to mediate antibody-
dependent cellular cytotoxicity (ADCC) (Moreno et al.,
2007), are increased and correlate with a better prognosis
(Treon et al., 2000; Hamanaka et al., 2003). However, in some
cancer patients the presence ofMUC1 antibodies is decreased,
due to immune complex formation with circulating MUC1
(Kotera et al., 1994; Treon et al., 2000). It can be anticipated
that enhancement of anti-MUC1 immune responses by
immunotherapy could induce strong anti-tumour responses.
Studies using MUC1 antibody-, MUC1 peptide-, or DC-based
vaccination strategies have been shown to be safe and
feasible (Sorensen et al., 2006; Wierecky et al., 2006; Lepisto
et al., 2008; Julien et al., 2009). Additionally, these studies
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cancer patients.
Besides following clinical outcome, there is an urgent need
for tools which monitor immune responses against tumour-
associated, aberrant MUC1 glycosylation patterns. The most
tested system to measure antibodies against MUC1 is an
ELISA where a peptide containing 5 tandem repeats of MUC1
(MUC1-100mer ELISA) is coated. Even though this system has
proved its merit detecting quantitative differences between
cancer patients and healthy controls (von Mensdorff-Pouilly
et al., 2000a,b), it is clear that it does not detect glycospeciﬁc
antibodies. The use of small synthetic glycopeptides would
allow detection of these glycospeciﬁc antibodies. When using
an array of these glycopeptides it is clear such a system can be
used tomap the reactivity of patients towards speciﬁc parts of
MUC1 and to study the role of speciﬁc antibody reactivities as
a biomarker (Wandall et al., 2010). However, both method-
ologies do not detect antibodies which recognize conforma-
tion speciﬁc structures of MUC1. It can be anticipated that
monitoring of humoral immune responses with a system that
detects responses to underglycosylatedMUC1might correlate
betterwith clinical responses than evaluationwith the current
available techniques (Rosenberg et al., 2005). Therefore, it is
relevant to develop a system inwhichMUC1 glycosylation can
be manipulated to detect immune responses against these
underglycosylated MUC1 epitopes.
In this study, we aim to develop a method to evaluate the
presence of antibodies recognizing the native conformation of
MUC1-Tn epitopes in serum using ﬂow cytometry. To this end,
wemade use of the Chinese Hamster Ovary (CHO) ldlD cell line,
which is deﬁcient in its UDP-galactose/UDP-N-acetylgalactosa-
mine 4-epimerase enzyme (Krieger et al., 1981; Kingsley et al.,
1986). This enzyme is crucial for the formation of UDP-Gal and
UDP-GalNAc from UDP-Glc/GlcNAc and as a consequence both
N-linked and O-linked glycosylation are affected by the defect.
The glycosylation can be restored by providing the CHO-ldlD cell
withexogenous sourcesofGal andGalNAc (Kingsleyet al., 1986).
We used CHO-ldlD cells stably transfected with a full
coding sequence of the MUC1 protein (32 tandem repeats),
enabling the production of cells expressing speciﬁc MUC1
glycoforms. After validation of this system by glycosylation-
speciﬁc as well as MUC1-speciﬁc antibodies, we used these
cells to screen antibodies recognizing MUC1-Tn epitopes in
sera from breast cancer patients, healthy controls and a breast
cancer patient vaccinated with a keyhole limpet hemocyanin-
conjugated truncated MUC1 peptide.
2. Materials and methods
2.1. Cell culture
CHO-ldlD and CHO-ldlD cells stably transfected with
MUC1F were cultured in Iscove's modiﬁed Dulbecco's
medium supplemented with 3% FBS, 1% penicilline/strepto-
mycin and 600 μg/ml G418. The UDP-Gal/UDP-GalNAc 4-
epimerase deﬁcient CHO-ldlD MUC1 cells and the CHO-ldlD
cells, which served as a negative control, were cultured for
3 days with 1 mM GalNAc (Sigma-Aldrich, St. Louis, MO,
USA), inducing them to express MUC1-Tn or with 1 mM
GalNAc and 0.1 mM Gal (Sigma-Aldrich), inducing them to
express MUC1-T (Fig. 1).2.2. Serum
Frozen serum (−20 °C) of ﬁve healthy controls and seven
breast cancer patients were obtained from the department of
clinical chemistry (Maastricht University Medical Center+). A
positive serum sample, from a breast cancer patient,
vaccinated with a keyhole limpet hemocyanin-conjugated
truncated MUC1 peptide, expressing anti-Tn-MUC1 antibo-
dies was used as a positive control (Sabbatini et al., 2007;
Wandall et al., 2010).
2.3. Antibodies
MUC1 antibody 214D4 (puriﬁed from the supernatant of
the 214D4 cell line (Wesseling et al., 1995)) was kindly
provided by Dr. J. Hilkens (the Netherlands Cancer Institute,
Amsterdam, the Netherlands), MAb 5E5 (Tarp et al., 2007)
and MAb 5F4 (Thurnher et al., 1993) were used for
ﬂowcytometric evaluation of MUC1 eptitope expression by
CHO-ldlD MUC1 cells. A detailed description of the speciﬁ-
cities of the MUC1 antibodies used in this study has been
published previously (van Leeuwen et al., 2006). Brieﬂy, the
MAb 214D4 recognizes human MUC1 irrespective of its
glycosylation pattern, MAb 5E5 exclusively recognizes
MUC1-Tn/STn and MAb 5F4 recognizes Tn epitopes irrespec-
tive of peptide backbone they are associated with.
2.4. Flow cytometry
CHO-ldlD and CHO-ldlD MUC1F cells supplemented with
either Gal, GalNAc, or Gal and GalNAC were incubated with
different antibodies (MAb 214D4, 5E5 or 5F4), washed and
incubated with the secondary antibody goat-anti-mouse R-
phycoerithrin (PE) labeled (BD Biosciences, San Jose, CA,
USA).
For the detection of human serum antibodies, CHO-ldlD
and CHO-ldlD MUC1 cells supplemented with either Gal,
GalNAc, or Gal and GalNAC were preincubated with rat
serum, washed and incubated with 20 and 40 times diluted
serum. Cells were then incubated with a secondary Donkey-
anti-Human R-phycoerithrin (PE) labeled antibody, which is
preabsorbed for rat (Jackson ImmunoResearch, West Grove,
PA, USA). 7-Amino-actinomycin D (7AAD) was used to
differentiate between viable and dead cells. All antibody
incubations were performed at 4 °C for 1 h. Reactivity of
antibodies with the CHO-ldlD and CHO-ldlD MUC1F cells was
analysed by ﬂow cytometry using a BD FACSSort (BD
Biosciences) and data were analysed with BD CellQuestTM
Pro Software (BD Biosciences).
3. Results
3.1. Detection of O-glycosylation of MUC1 after GalNAc and/or
Gal supplementation
To conﬁrm surface expression of MUC1 by the CHO-ldlD
MUC1 cells, reactivity of the cells with MAb 214D4,
recognizing MUC1 irrespective of its glycosylation was
analysed. The results of ﬂow cytometric analysis showed
that the non-transfected CHO-ldlD cells do not bind the
Fig. 2. Expression of MUC1 and MUC1-Tn epitopes by CHO-ldlDMUC1 cells as analysed by ﬂow cytometry. CHO-ldlD and CHO-ldlDMUC1 cells were cultured for
3 days in the presence or absence of GalNAc, Gal or the combination of GalNAc andGal. Analysed cellswere gated on 7AAD−. (A) Binding ofMAb214D4 (recognizing
MUC1) by CHO-ldlD cells and CHO-ldlD cells transfected with MUC1. (B) Binding of MAb 214D4, 5E5 (recognizing MUC1-Tn/STn) or MAb 5F4 (recognizing STn) by
CHO-ldlD and CHO-ldlDMUC1 cells culturedwith orwithout GalNAc. Binding ofMAb5E5 after addition of GalNAc andGal to the CHO-ldlDMUC1 cell culture. ND, not
determined.
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4,43 and 210, respectively) (Fig. 2A).
To evaluate whether the glycosylation defect of the CHO-
ldlD cells can be reversed by supplementing the culture
medium with GalNAc and/or Gal, we performed binding
experiments with antibodies speciﬁc for different MUC1-
assocated, O-glycan structures (or O-glycan haptens). O-
glycosylation of MUC1 is initiated after binding of GalNAc to
one of the glycosylation sites (threonine or serine), creating
the MUC1-Tn epitope. Thereafter, glycosylation is continued
by linking of Gal to the ﬁrst GalNAc (Fig. 1). To induce
glycosylation, CHO-ldlD and CHO-ldlD MUC1 cells were
cultured for 3 days in the presence of GalNAc, Gal or a
combination of both GalNAc and Gal. The cells were then
harvested and binding with MAb 5E5, which speciﬁcally
recognizes the combined glycopeptide epitope MUC1-Tn/STn
(Tarp et al., 2007), was assessed with ﬂow cytometry. When
CHO-ldlD MUC1 cells were cultured in medium supplemen-
ted with GalNAc, a shift in 5E5 binding signal was observed as
compared to CHO-ldlD MUC1 cells cultured without sugar
(MFI increased from 25 to 213) (Fig. 2B). This shift in 5E5
binding signal was not observed in untransfected CHO-ldlD
cells incubated with GalNAc. In addition to 5E5 MAb binding,
MUC1 glycosylation was further analysed by staining with
MAb 5F4, which recognizes Tn epitopes irrespective of the
peptide backbone. Also with this antibody, a shift in binding
signal was observed when CHO-ldlD MUC1 cells were
cultured in GalNAc-containing medium (MFI increased from
6,8 to 33) (Fig. 2B). These shifts in 5E5 and 5F4 bindingindicate that supplementation with GalNAc results in MUC1-
Tn epitope formation.
When in addition to GalNAc also Gal was added to the
medium, decreased binding of MAb 5E5 was detected
(Fig. 2B), indicating that glycosylation proceeds after Gal
linking to the ﬁrst GalNAc. In contrast, neither supplemen-
tation of Gal alone to the CHO-ldlD MUC1 cells nor the
addition of anymonosaccharide to the CHO-ldlD cells resulted
in the formation of MUC1-Tn epitopes (data not shown).
These data reveal that it is possible to reconstitute MUC1 O-
glycosylation in the CHO-ldlD MUC1 cells by GalNAc supple-
mentation, which results in MUC1-Tn epitope formation and
if Gal is also supplemented the surface expression of these
epitopes decreases (MFI 6.9).
3.2. Optimization of CHO-ldlD MUC1 ﬂow cytometric analysis
The use of CHO-ldlD cells for ﬂow cytometric analysis is
complicated by the culture characteristics of the CHO-ldlD
cells and therefore needed optimization. Since the CHO-ldlD
cells scavenge themedium for free Gal and GalNAc, theymust
be cultured at low serum concentrations, to preserve the
glycosylation defect. Additionally, because CHO-ldlD cells are
adherent, the generation of a single cell suspension is
accompanied by cell death. Dead cells are responsible for a
speciﬁc binding of antibodies and co-staining with 7AAD
showed that in the 7AAD positive population there is a
subpopulation clearly positive for the MUC1 antibodies
(Fig. 3A). Moreover, reactivity with isotype antibody control
Fig. 3. Optimization of CHO-ldlD culture for ﬂow cytometric analysis. (A) CHO-ldlD cells were cultured in monolayer were scraped, incubated with isotype (IgG1)
and anti-MUC1 antibodies (MAb 214D4 and 5E5). Before analysis cells were stained with 7AAD. Without gating (left panel) a population of CHO-ldlD cells is
positive for all antibodies, which is due to the two subpopulations of 7AAD+ cells (middle panel) and which not present after gating on 7AAD− cells (right panel).
(B) Comparison antibody (isotype, 214D4, 5E5) binding of CHO-ldlD MUC1 cells after being scraped or trypsinized.
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7AAD positive cells.
To decrease the number of dead cells and increase the
yield, two different harvesting techniques were evaluated.
Cell scraping was compared with trypsinization of the CHO-
ldlD MUC1 cells. In contrast to cell scraping, trypsinization
reduced the number of dead cells by 30%, however ﬂow
cytometric analysis showed that trypsinization induced
expression of new epitiopes reactive with the MUC1 speciﬁc
antibodies, but not isotype control antibody (Fig. 3B).
Cleaving of the MUC1 peptide by trypsin could be responsible
for this new epitope formation. Even though cell scraping
induces a lot of cell death, it remains the preferred option in
this system since dead cells can be excluded using 7AAD
staining.
3.3. Detection of serum antibodies directed to MUC1-Tn/STn
epitopes in healthy controls and (vaccinated) breast cancer
patients
As shown in Fig. 2, the CHO-ldlDMUC1 system is effective
in generating MUC1-Tn epitopes. To analyse if MUC1-Tn
antibodies are present in sera of breast cancer patients as well
as in healthy controls, CHO-ldlD MUC1 cells were cultured in
the presence or absence of GalNAc and prior to ﬂowcyto-
metric analysis cells were incubated with human serum. The
CHO-ldlD cells were taken along as a negative control, to
exclude aspeciﬁc or speciﬁc reactivity. Secondary antibody
staining was performed for detection of serum antibodies toMUC1 and MUC1-Tn. Both anti-human IgM- and IgG-
detecting secondary antibodies were used to discriminate
between primary (IgM) and secondary humoral responses
(IgG). Healthy controls as well as breast cancer patients did
not show speciﬁc binding of serum antibodies with CHO-ldlD
MUC1 cells cultured with or without GalNAc. Eventhough in
the serum of breast cancer patients repetitively a marginal
shift of the histogram could be observed when a secondary
IgM-recognizing antibody was used, this shift did not reach
signiﬁcance (Fig. 4A).
In contrast, a post-vaccination serum sample of a breast
cancer patient vaccinatedwith a keyhole limpet hemocyanin-
conjugated truncated MUC1 peptide, which was tested
positive for antibodies directed to aberrantly glycosylated
MUC1 by O-glycopeptide microarray (Wandall et al., 2007),
showed a much higher binding signal after incubation with
CHO-ldlD MUC1 cells (increase in MFI of anti-IgG binding
from 53.7 to 127 and of anti-IgM binding from 5.4 to 9.4).
Moreover, both IgG and IgM antibodies directed to MUC1-Tn
antibodies were present in this serum (increase in MFI of
anti-IgG binding from 91.7 to 143 and of anti-IgM binding
from 8.4 to 12.9) (Fig. 4A). To conﬁrm that the reactivity to
CHO-ldlD MUC1 cells cultured with GalNAc was actually
directed to MUC1-Tn epitopes and not to the MUC1 protein,
antibody reactivity to CHO-ldlD MUC1 cells cultured with
GalNAc and Gal, restoring glycosylation, was additionally
analysed. No antibody reactivity was detected if serum was
incubated with these CHO-ldlD MUC1 cells (Fig. 5B), indicat-
ing that the antibodies were indeed MUC1-Tn speciﬁc.
Fig. 4. Presence ofMUC1-Tn antibodies in serumof breast cancer patients and healthy controls. CHO-ldlD and CHO-ldlDMUC1 cellswere cultured for 3 days in the presence
or absence of GalNAc, Gal or the combination of GalNAc and Gal. Cells were incubated with serum, analysed by ﬂow cytometry and gated on 7AAD−. (A) Expression o
MUC1 andMUC1-Tn IgG and IgM antibodies by breast cancer patients (representative data of one out of seven patients), healthy controls (representative data of one out o
ﬁve patients) or a breast cancer patient, vaccinated with a keyhole limpet hemocyanin-conjugated truncated MUC1 peptide (this sample was tested in two independen
experiments). Only the serum from the vaccinated patient contained MUC1-Tn IgG and IgM antibodies and thus reacted with the CHO-ldlD MUC1 cells cultured with
GalNAc, however (B) when CHO-ldlDMUC1 cell were cultured in the presence of both Gal and GalNAc, reactivity with the anti-IgG antibody decreased.
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In the present study we describe a ﬂow cytometric
method to detect both MUC1 and MUC1-Tn antibodies in
human serum. To this end, we used CHO-ldlD cells stably
transfected with MUC1. Due to its UDP-Gal/UDP-GalNAc 4-
epimerase enzyme deﬁciency, the glycosylation of MUC1 can
be effectively manipulated by addition of different mono-
saccharides. Supplementation of GalNAc to the cell culture
results in the formation of the cancer-associated MUC1-Tn
epitope that can be detected by ﬂow cytometry using
glycospeciﬁc MUC1 antibodies. Additionally, the detection
of these MUC1-Tn epitopes is decreased after supplementa-
tion of both Gal and GalNAc, which presumably is caused by
extension of glycosylation. The capacity of CHO-ldlD cells to
express MUC1-Tn antigens, as detected by cytospin analysis,
has been reported by Sørensen et al. (Sorensen et al., 2006). In
this report, we extend these observations by showing that
expression of MUC1 and MUC1-Tn epitopes can also be
detected with ﬂow cytometry, which allows a more sensitive
quantiﬁcation of MUC1 and MUC1-Tn expression (Kas-
Deelen et al., 1998).f
f
tWith the CHO-ldlDMUC1-based ﬂow cytometric assay, we do
not detect serum antibodies against the unglycosylatedMUC1
protein in non-vaccinated breast cancer patients. However,
both IgG and IgM antibodies can be detected in the serum of a
breast cancer patient vaccinated with a truncated MUC1
peptide, indicating that immune responses induced by
immunotherapy can be detected with this ﬂow cytometric
system. Detection of antibodies against unglycosylated MUC1
seems to be in apparent contrast with previous reports by
Altschuler et al., who showed that CHO-ldlD cells rapidly
endocytose and degrade non-glycosylated surface MUC1
(Altschuler et al., 2000). Nevertheless, we show that MUC1
expression can be detected by ﬂow cytometry with MAb
214D4 when the CHO-ldlD culture is not supplemented with
any carbohydrate, indicating that CHO-ldlD still express
surface MUC1.
Detection by ELISA and Western blot of anti-MUC1
antibodies in serum of cancer patients as well as healthy
controls has been described previously. However, the
percentage of patients and controls expressing these anti-
bodies show large variations between studies (Nakamura
et al., 1998; Treon et al., 2000; von Mensdorff-Pouilly et al.,
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serum antibodies could not be detected in healthy controls
(Apostolopoulos et al., 2006), whereas other studies demon-
strated that up to 16% of healthy controls show reactivity to
MUC1 peptides (Nakamura et al., 1998). In cancer patients,
the reported levels of anti-MUC1 antibodies also differ, due to
the presence of soluble serum MUC1. Depending on tumour
type, these serum MUC1 antigens have been shown to
complex with anti-MUC1 antibodies (Treon et al., 2000).
Standardization of the different methods, including the
ﬂowcytometric assay we describe, seems to be necessary to
answer the question on prevalence of anti-MUC serum
antibodies in healthy controls and cancer patients. The
numbers of samples tested in this study does not justify a
conclusion on prevalence of these antibodies; we merely
show that with this technique we are able to detect human
serum antibodies directed to MUC1 and underglycosylated
MUC1.
In addition to the detection of serum antibodies against
unglycosylatedMUC1,manipulation ofMUC1 glycosylation in
the CHO-ldlD MUC1 system allowed us to selectively test for
the presence of IgG and IgM antibody responses to MUC1-Tn.
These serum antibodies could only be detected in a breast
cancer patient after vaccination and not in non-vaccinated
cancer patients or healthy controls. Detection of antibodies
directed to underglycosylated MUC1 has been recently
described by Wandall et al. (2010), who made use of an O-
glycopeptide microarray to demonstrate that MUC1-Tn/STn
associated IgG serum antibodies are present in low numbers
of newly diagnosed breast, ovarian and prostate cancer
patients and not in healthy controls. Additionally, in patients
who had no pre-existing MUC1-Tn/STn IgG antibodies, it was
shown that they did develop detectable serum IgG and IgM
MUC1-Tn antibodies after vaccination. Similar ﬁndings were
previously described by Sabbatini et al. (2007), who demon-
strated that MUC1-Tn antibodies could be detected by ELISA.
Both ELISA and O-glycopeptide microarrays make use of
small MUC1 peptides that are differently glycosylated. The O-
glycopeptide microarray allows rapid mapping of serum
antibody speciﬁcity and has already been proven to be
reliable in detection of MUC1 serum antibodies in mice
vaccination studies (Westerlind et al., 2009). Even though the
glycosylation sites can be controlled in the small peptide-
based methods, allowing speciﬁc antibody mapping, these
methods are only able to detect antibodies binding to linear
MUC1 structures. In contrast to this highly sensitive method,
which can be efﬁciently used for detection of cancer
biomarkers, the CHO-ldlD MUC1 system is able to detect
antibodies to the native, three-dimensional MUC1. Moreover,
since it is a cellular system, it is possible to do in vitro
functionality studies like ADCC and complement activation.
Thismakes the CHO-ldlDMUC1 system complementary to the
previously published methods to detect MUC1 serum anti-
bodies, since the clinical signiﬁcance of underglycosylated
MUC1-antibodies in relation to cancer is largely unknown.
In conclusion, we report on a cellular, ﬂow cytometry-
based technique to detect serum MUC1-Tn antibodies. We
show that it is a unique system to detect antibodies binding to
the native underglycosylated MUC1 protein and can be
effectively used for antibody monitoring and functional
assays.References
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